Most patients with hypertension need more than one drug to achieve blood pressure (BP) control. This randomized, double-blind, multifactorial study evaluated whether combinations of aliskiren and amlodipine provided superior BP reductions to component monotherapies in patients with hypertension (mean sitting diastolic BP (msDBP) 95-o110 mm Hg). Overall, 1688 patients were randomized to once-daily monotherapy with aliskiren 150 or 300 mg or amlodipine 5 or 10 mg, combination therapy with one of four corresponding aliskiren/amlodipine doses, or placebo for 8 weeks. At week 8 end point, aliskiren/amlodipine combinations provided significant msDBP reductions from baseline of 14.0-16.5 mm Hg, compared with reductions of 8.0 and 10.2 mm Hg for aliskiren 150 and 300 mg, respectively (Po0.001), and 11.0 and 13.8 mm Hg for amlodipine 5 and 10 mg, respectively (Po0.05). Aliskiren/amlodipine combinations provided reductions in mean sitting systolic BP 20.6-23.9 mm Hg, compared with decreases of 10.7 and 15.4 mm Hg for aliskiren 150 and 300 mg, respectively (Po0.001), and 15.8 and 21.0 mm Hg for amlodipine 5 (Pp0.001) and 10 mg (P ¼ NS), respectively. Aliskiren/amlodipine combination therapy provides greater BP lowering than either agent alone, hence offering an effective treatment option for patients with hypertension.
INTRODUCTION
Patients with hypertension are at increased risk of cardiovascular events compared with healthy individuals. Most patients are likely to need more than one agent to achieve blood pressure (BP) target. Current United States and European treatment guidelines for patients with BP420/10 mm Hg above goal, or those at high risk of developing cardiovascular events recommend that therapy is initiated with two agents from different therapeutic classes. 1, 2 The direct renin inhibitor aliskiren offers a different option for inhibiting the renin-angiotensin-aldosterone system (RAAS) to angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). Aliskiren targets the rate-limiting step of the RAAS by directly inhibiting the enzyme renin, thereby reducing the plasma renin activity (PRA) and all other downstream components of the system (angiotensin I, angiotensin II and aldosterone). 3 Hence, aliskiren may provide more effective RAAS suppression than that produced by ACE inhibitors or ARBs, which both increase PRA. The BP-lowering effects of aliskiren/amlodipine combination therapy were demonstrated in 1254 patients with hypertension in the ACCELERATE study (aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control). Patients who received initial combination therapy with aliskiren/amlodipine achieved a significant additional reduction from baseline in systolic BP of 6.5 mm Hg (Po0.0001) over 8-24 weeks of treatment compared with those who received first-line treatment with either agent as monotherapy (with subsequent addition of the other drug). 4 The aim of this randomized, double-blind, multifactorial study was to assess the efficacy, safety and tolerability of four aliskiren/ amlodipine dose combinations (150/5, 150/10, 300/5 and 300/10 mg) administered as single-pill combinations compared with those of the component monotherapies in patients with hypertension. Aliskiren/ amlodipine combinations have been approved in the United States for the treatment of hypertension as initial therapy in patients likely to need multiple drugs to control BP, as a replacement in patients whose BP is not controlled with either monotherapy or as a substitute for its components given in combination.
MATERIALS AND METHODS Patients
Men and women aged X18 years with primary hypertension were eligible for inclusion in the study. All patients had to have mean sitting diastolic BP (msDBP) X95 mm Hg and o110 mm Hg at randomization. The main exclusion criteria were grade III hypertension (msDBP X110 mm Hg or mean sitting systolic BP (msSBP) X180 mm Hg), secondary hypertension, a history of severe cardiovascular or cerebrovascular disease, type 1 or type 2 diabetes mellitus that was not well controlled (glycosylated hemoglobin [HbA1c] 48.0%), and severe renal impairment (glomerular filtration rateo30 ml min À 1 at visit 1, a history of dialysis, or a history of nephrotic syndrome) or hepatic disease (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values exceeding 3 Â upper limit of normal (ULN) at visit 1, a history of hepatic encephalopathy, a history of esophageal varices or a history of portocaval shunt). Women of childbearing potential had to be using effective contraceptive methods for inclusion in the study; pregnant or lactating women were excluded. 1 All patients submitted written informed consent before participating in any study procedure. The study was conducted in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice and the Declaration of Helsinki. This study and any amendments were reviewed by the Independent Ethics Committee or the Institutional Review Board for each center. The trial was conducted according to the ethical principles of the Declaration of Helsinki and is registered with clinicaltrials.gov (identifier: NCT00739973).
Study design
The present double-blind, multicenter, randomized, placebo-controlled, multifactorial study was conducted at 208 centers across 18 countries (Argentina, Australia, Canada, Colombia, Denmark, Finland, Greece, Italy, Mexico, Panama, Peru, Romania, Russia, South Africa, Spain, Sweden, Taiwan and the United States).
Following a 3-day washout and a 2-or 4-week placebo run-in period, eligible patients with msDBP X95 mm Hg and o110 mm Hg who met other inclusion criteria were randomly assigned in an equal ratio, using a validated interactive voice response system, to one of the following oncedaily treatment groups: aliskiren 150 mg, aliskiren 300 mg, amlodipine 5 mg, amlodipine 10 mg, or the single-pill combination of aliskiren/ amlodipine 150/5 mg, aliskiren/amlodipine 150/10 mg, aliskiren/amlodipine 300/5 mg, aliskiren/amlodipine 300/10 mg or placebo. Patients assigned to amlodipine 10 mg, or aliskiren/amlodipine 150/10 or 300/ 10 mg began treatment with amlodipine 5 mg, or aliskiren/amlodipine 150/5 or 300/5 mg, respectively, and were force-titrated to the higher amlodipine doses after 1 week of treatment. Treatment was administered once daily at B0800 hours, except on clinic visit days, when patients were instructed to delay the treatment until all assessments had been completed.
Study assessments
The primary objective of the study was to assess whether antihypertensive efficacy of the combination of aliskiren/amlodipine was superior to each of the component monotherapies, as assessed by change in msDBP from baseline to week 8 end point across doses. Secondary efficacy variables included change in msSBP from baseline to week 8 end point and the proportion of patients achieving BP control (o140/90 mm Hg) at week 8 in each treatment group. The effect of study treatments on mean 24 h ambulatory BP was assessed as change from baseline to week 8 end point in a subgroup of patients. Changes in PRA from baseline to week 8 end point were also measured in a subset of patients.
BP measurements
Clinic (office) BP was measured using an OMRON (models HEM 705CP or HEM 705IT) BP monitor with an appropriate cuff size, in accordance with the British Hypertension Society Guidelines. 5 The sitting BP was measured after the patient had been sitting for at least 5 min; three measurements were made at each study visit and the mean of these was used as the value for that visit. BP was measured at trough (24±3 h after the previous dose).
Ambulatory BP monitoring
Ambulatory BP monitoring was conducted at baseline and week 8 in a subset of patients (n ¼ 819). Measurements were made using a SpaceLabs 90207 ambulatory BP monitoring device (Spacelabs, Redmond, WA, USA). The device was attached to the non-dominant arm of the patient between 0700 and 1000 hours; BP was automatically measured every 15 min between 0600 and 2159 hours, and every 20 min between 2200 and 0559 hours. The patient wore the device for a minimum of 24 h.
RAAS biomarker analyses
The effect of study treatments on PRA was evaluated in a predefined subset of patients (n ¼ 608; approximately one third of patients) at baseline and at week 8 end point. Blood was collected from patients in the sitting position who were calm, and had been seated for at least 10 min. PRA was measured at a central laboratory by radioimmunoassay of generated angiotensin I (DiaSorin kit; DiaSorin, Stillwater, MN, USA).
Safety, tolerability and laboratory evaluations
All adverse events (AEs) and serious AEs were recorded throughout the study and assessed by the investigator for their relationship to study medication. Hematology, blood chemistry, urine values and vital signs were monitored regularly.
Statistical analyses
The primary efficacy variable (change in msDBP from baseline to week 8 end point) was assessed by Hung's AVE test. 6 If this test was statistically significant, the contribution of the individual monotherapies to the BP reduction with each combination was assessed using a two-way analysis of covariance model with treatment and region as factors, and baseline msDBP as a covariate. Pairwise comparisons were performed at a two-sided significance level of 0.05. Changes in msSBP from baseline to week 8 were assessed in the same way as for the primary efficacy variable, except that the analysis of covariance model included baseline msSBP as a covariate.
The proportion of patients in each treatment group achieving BP control (o140/90 mm Hg) at week 8 end point were compared using a logistic regression model with treatment and region as factors, and baseline msDBP as a covariate. Changes in hourly mean ambulatory diastolic BP were assessed using a two-way repeated-measures analysis of covariance model with treatment and region as factors, and baseline 24 h mean ambulatory diastolic BP as a covariate. Mean ambulatory systolic BP was assessed using the same model, except that baseline 24 h mean ambulatory systolic BP was used as a covariate. PRA measurements were calculated as geometric means; changes from baseline to week 8 were calculated as the ratio of geometric means at week 8 end point to baseline.
A sample size of 1449 patients completing the study (161 per arm) was targeted to provide 90% power to detect that combination therapy was different from both monotherapies at a two-sided significance level of 0.05 (assuming a treatment difference in msDBP of 3.2 mm Hg and a s.d. of 8 mm Hg). The study investigators therefore aimed to randomize 1611 patients (179 per arm), assuming a withdrawal rate of 10%.
The full analysis set, used for all efficacy analyses, excluded patients randomized incorrectly, those who did not receive study drug and those who did not have a post-baseline efficacy measurement. For end point analyses, the last observation was carried forward for patients who did not have a measurement at week 8. Analyses of ambulatory BP and PRA were performed in subsets of patients from the full analysis set. The safety set consisted of all randomized patients who received double-blind trial medication. All statistical analyses were performed using SAS software version 8.2 (SAS Institute, Inc., Cary, NC, USA).
RESULTS

Patient disposition and baseline characteristics
A total of 1688 patients were randomized and 1539 patients (91%) completed the study (Figure 1) . Overall, the most common reason for discontinuation during the double-blind period was unsatisfactory therapeutic effect. The incidence of unsatisfactory therapeutic effect was lower in the combination groups (0.5-1.1%) than in the placebo (8.6%) and monotherapy (1.1-4.1%) groups. Other common reasons for discontinuation included AEs and withdrawal of consent, with the incidence generally similar across treatment groups (Figure 1 ).
Demographics and baseline characteristics were broadly similar across treatment groups ( Table 1) . The randomized population consisted mainly of Caucasian (62.1%) and Black (19.9%) patients; the mean patient age was 54.1 years, with 17.2% of participants aged 65 years or older. Almost half (46.0%) of the patients were obese (body mass index X30 kg m À 2 ), and 11.0% of participants had diabetes. The overall msSBP/diastolic BP at baseline was 157.3/99.7 mm Hg, and mean BP values were similar across the treatment groups. a Three patients who were ineligible for entry into the double-blind period of the study were mistakenly randomized (one in the ALI 150-mg group and two in the ALI/AML 150/10-mg group); they did not receive medication and took no further part in the study. ALI, aliskiren; AML, amlodipine. Table 2 ). Aliskiren/amlodipine 300/ 10 mg combination therapy enabled 68.3% of patients to achieve BP control at week 8 end point.
Ambulatory BP In the subgroup of 819 patients who underwent 24 h ambulatory BP monitoring, all active treatments provided greater reductions from baseline in 24 h mean ambulatory diastolic BP than placebo (4.3-13.0 mm Hg vs an increase of 0.7 mm Hg; Po0.001; Table 3 ). The four aliskiren/amlodipine dose combinations provided significantly greater reductions than the corresponding monotherapies (Po0.001). Reductions in 24 h mean ambulatory systolic BP were also larger with all active treatments than with placebo (Po0.001), and all aliskiren/amlodipine combinations provided significantly greater reductions than the respective monotherapies Po0.001 vs amlodipine. The P value indicates the significance of combination therapy vs the component dose of the amlodipine monotherapy. Data shown are for the full analysis set at week 8 end point. BP control was defined as BPo140/90 mm Hg.
Aliskiren/amlodipine combination for hypertension TW Littlejohn III et al (Po0.001; Table 3 ). Greater reductions in ambulatory BP with aliskiren/amlodipine 300/10 mg, compared with those achieved with either monotherapy, were seen at each hour throughout the 24 h dosing period ( Figure 3 ). Similar trends were seen for the other doses (data not shown).
RAAS activity PRA was measured in a subgroup of 608 patients at baseline and at week 8 end point. Aliskiren 150 and 300 mg monotherapy reduced PRA by up to 68.3%, whereas amlodipine 5 and 10 mg monotherapy increased it by up to 72.9% ( Figure 4 ). All aliskiren/ amlodipine dose combinations neutralized amlodipine-induced increases in PRA, and reduced PRA by 54.9-68.1%.
Safety and tolerability
Aliskiren, alone and in combination with amlodipine, was generally well tolerated ( Table 4 ). The incidence of total AEs ranged from 31.4 to 44.6% in all active treatment groups, and was 37.4% in the placebo group. The incidence of serious AEs was low (0.5% overall), and there were no deaths or discontinuations from the study owing to serious AEs. A total of nine patients (two in the placebo group and seven patients in treatment groups) experienced serious AEs, such as retinal detachment, abdominal mass, bronchitis, calculus ureteric, cerebrovascular accident, gastroenteritis, hand fracture, hydronephrosis and pneumonia. None of the serious AEs were suspected to be related to the drug being studied. The overall incidence of discontinuations owing to AEs was low (1.7%), but was higher in the amlodipine 10-mg group (n ¼ 7; 3.9%) than in the other groups (n ¼ 1-4; 0.5-2.2%). Most AEs were mild or moderate in severity.
Headache occurred most frequently in the placebo group (10.1%). As expected, rates of peripheral edema were greater in treatment groups containing amlodipine 10 mg (amlodipine 10 mg monotherapy, 13.8%; aliskiren/amlodipine 150/10 mg combination, 7.7%; aliskiren/amlodipine 300/10 mg combination, 13.6%) than in other treatment groups (1.0-4.3%).
Few patients had abnormal laboratory test values (Table 4 ). The incidence of serum potassium levels 45.5 mmol l À 1 was low (0-1.2%). Serum creatinine levels 4176.8 mmol l À 1 were observed in one patient in the aliskiren/amlodipine 300/5-mg group (0.6%), and blood urea nitrogen levels 414.28 mmol l À 1 were reported in three patients (one each in the placebo, aliskiren/amlodipine 150/5 mg and aliskiren/amlodipine 300/5-mg groups).
DISCUSSION
The present study showed that initial combination therapy with aliskiren and amlodipine provided significant additional BP reductions over those achieved with the respective monotherapies and was generally well tolerated in patients with mild-tomoderate hypertension.
Previous clinical trials have demonstrated that aliskiren/ amlodipine combination therapy provides significant additional BP reductions over those obtained with amlodipine monotherapy in patients with hypertension. 7 Aliskiren/amlodipine combination therapy has also demonstrated BP-lowering efficacy during longterm treatment. 8 This study demonstrated the greater BP-lowering effect of aliskiren/amlodipine single-pill combination compared with each mono-component, indicating the contribution from each monocomponent toward combination. Treatments that combine two antihypertensive agents in a single pill may offer patients a more convenient option than the free combination because they reduce the pill burden and thus simplify the dosing regimen. A metaanalysis has shown that combination therapy was associated with improved compliance compared with use of the free combinations. 9 Moreover, an increase in the number of prescribed medications has been associated with a reduction in treatment adherence. 10 Patient adherence to a prescribed treatment regimen is a key factor in managing hypertension, and is associated with better cardiovascular outcomes compared with suboptimal adherence. [11] [12] [13] Low-dose combination therapy may also confer advantages in terms of safety over higher dose of monotherapy. In the present study, aliskiren/amlodipine combination at low dose of 150/5 mg produced similar BP lowering, but significantly lower rate of peripheral edema as compared with amlodipine monotherapy at high dose of 10 mg. This is consistent with the previous findings. 14 In our study, aliskiren monotherapy reduced PRA by 61-68% from baseline at week 8 end point, whereas amlodipine monotherapy increased PRA by 59-73%. The combination of aliskiren and amlodipine reduced PRA to a similar extent as aliskiren monotherapy; thus, aliskiren neutralized the increase in PRA observed with amlodipine alone.
Combination therapy with aliskiren and amlodipine was generally well tolerated during the trial. This is consistent with the findings of previous studies. 4, 7, 15 Most AEs reported during the present study were mild or moderate in severity, and few patients experienced serious AEs or discontinued participation because of AEs. Overall, aliskiren/amlodipine combination therapy had a similar safety and tolerability profile to that of the individual monotherapies, with no evidence of new treatment-emergent AEs. In summary, the present study shows that aliskiren/amlodipine combination therapy provides significantly greater BP reductions and improved rates of BP control than the respective monotherapies in patients with hypertension after 8 weeks of treatment. Combination therapy was well tolerated, with a similar safety and tolerability profile to those of the individual monotherapies. Aliskiren/amlodipine combination offers a convenient and effective option for the treatment of patients with hypertension.
What is known about this topic Most patients are likely to need two or more agents to achieve BP control. A well-established combination therapy regimen involves use of the complementary mechanisms of action of an inhibitor of the reninangiotensin-aldosterone system, in conjunction with a calcium channel blocker. The direct renin inhibitor aliskiren, in combination with the calcium channel blocker amlodipine, has been approved in the United States as an initial treatment for hypertension in patients likely to need multiple drugs to control BP, as replacement therapy for patients not achieving BP control with either monotherapy or as a substitute for the individual components given in combination.
What this study adds Aliskiren/amlodipine combination therapy at doses of 150/5, 150/10, 300/5 mg and 300/10 mg for 8 weeks provided clinically relevant BP reductions of 20.6-23.9/14.0-16.5 mm Hg, with additional leastsquares mean reductions over all respective monotherapies. Combination therapy resulted in BP control rates of 49-68%. Aliskiren/amlodipine combination therapy provides an effective treatment option for patients with hypertension.
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